Current usage of PSMA PET agents in the urology clinic

In this video, Edward M. Schaeffer, MD, PhD, discusses current uses for PSMA-PET in prostate cancer. Schaeffer is chair and Harold Binstein Professor of Urology at Northwestern University Feinberg School of Medicine in Chicago, Illinois.

Transcription:

What are current applications for PSMA PET agents in the urology clinic?

PSMA PET imaging is used in the initial diagnostic staging and then in subsequent cases where there can be a recurrence after primary treatment. Those are the 2 main areas where PET PSMA is used. And then as I mentioned, there's also FDA approval to use PSMA-linked radiotracers in the castrate-resistant space for treatment. So the imaging agents for staging are used up front new diagnoses unfavorable intermediate, high, and very high risk prostate cancer by NCCN definitions. In the recurrence space, if your PSA is rising and you've met the technical definition of recurrence, which is a PSA over .2 by AUA guidelines and by NCCN, it would fit that umbrella of a recurrence and then also post radiation, the Phoenix criteria; that is nadir plus 2. You can use PET imaging in the initial staging and then you can use it in the space where there's a recurrence, and that's a general admission criteria to get one of those tests.

This transcription was edited for clarity.